Modelling and clinical trials in paediatrics;Modélisation et essais cliniques en pédiatrie

Therapie

Volumn 60, Issue 4, 2005, Pages 385-390

  Jacqmin, Philippe ^a   Labouret, Nathalie ^b   Gueyffier, François ^c,d  

^a Exprimo NV   (Belgium)

^b AFSSAPS   (France)

^c Centre d'Investigation Clinique   (France)

^d LOUIS PRADEL HOSPITAL   (France)

Author keywords

Clinical trials; Modelling; Paediatric medicine; Simulation

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN; MIDAZOLAM; SULFANILAMIDE; THALIDOMIDE; UNCLASSIFIED DRUG;

BODY WEIGHT; CONFERENCE PAPER; DEMOGRAPHY; DISEASE COURSE; DRUG FATALITY; DRUG INDUSTRY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; EXPERIMENTAL MODEL; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; KIDNEY CLEARANCE; LAW ENFORCEMENT; MATHEMATICAL MODEL; MEDICAL EDUCATION; MEDICAL ETHICS; PEDIATRICS; PHYSICIAN; POPULATION MODEL; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROBLEM SOLVING; RISK ASSESSMENT; SAMPLE SIZE; SIDE EFFECT; SIMULATION; TREATMENT OUTCOME; UNIVERSITY; VALIDATION PROCESS;

EID: 29144448311     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005055     Document Type: Conference Paper

References (30)

1. Section 111: Pediatric studies of drugs. Food and Drug Administration Moderization Act of 1997 [online]. Available from URL: http://www.fda.gov/cder/ pediatric [Accessed 2005 Aug 8]
2. Pediatric Rule 1998 [online]. Available from URL: http://www.fda.gov/ cder/pediatric [Accessed 2005 Aug 8]
3. Public law 107-109, Best Pharmaceuticals for children Act 2001 [online]. Available from URL: http://www.fda.gov/cder/pediatric [Accessed 2005 Aug 8]
4. Pediatric Research Equity Act of 2003 [online]. Available from URL: http://www.fda.gov/opacom/laws/prea.html [Accessed 2005 Aug 8]
5. Proposal for a Regulation of the Council and of the Parliament on Medicinal Products for Paediatric Use [online]. Available from URL: http://pharmacos.eudra.org/F2/Paediatrics/Index.htm [Accessed 2005 Jul 6]
6. Chalumeau M, Treluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000; 83 (6): 502-5
7. Fontan JE, Combeau D, Brion F. Pediatric drug preparations in French hospitals: Pediatric Group of the French Clinical Pharmacy Society. Arch Pediatr 2000; 7 (8): 825-32
8. Botting J. The history of thalidomide. Drug News Perspect 2002; 15 (9): 604-11
9. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320 (7227): 79-82
10. Impicciatore P, Pandolfini C, Bonati M. Database could give children safer medicines [letter]. Nature 2000; 405 (6789): 882
11. Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52 (1): 77-83
12. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279 (15): 1200-5
13. Piotrovsky V. Population pharmacodynamic and pharmacokinetic modelling via mixed effects. Current Opin Drug Discov Devel 2000; 3 (3): 314-30
14. Sheiner L, Steimer JL. Pharmacokinetic/pharmacodynamic modelling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95
15. Johnson T, Tanner M, Taylor C, et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effects of celiac disease and cystic fibrosis. Br J Clin Pharmacol 2001; 51: 451-60
16. Johnson T. The development of drug metabolizing enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 37-48
17. Reid AW, Anderson BJ, Futter ME. Relationship of muscle strength to potassium concentration in a hypokalaemic infant. Anaesth Intensive Care 1997; 25 (5): 525-7
18. Funck GA, Fischer M, Joos B. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acquir Immune Defic Syndr 2001; 26 (5): 397-404
19. Mandema J, Verrota D, Sheiner L. Pharmacometrics: building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20 (5): 511-28
20. Sheiner L. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61 (3): 275-91
21. Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001; 45 (1): 150-7
22. Holford N, Kimko H, Monteleone J, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209-34
23. Girard P, Cucherat M, Guez D. Simulation des essais cliniques dans le développement des médicaments. Therapie 2004; 59 (3): 287-304
24. Patoux A, Bleyzac N, Boddy A, et al. Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. Eur J Clin Pharmacol 2001; 57: 297-303
25. Rubie H, Doz F, Vassal G, et al. Individual dosing of carbolplatin based on drug monitoring in children receiving high-dose chemotherapy. Eur J Cancer 2003; 39: 1433-8
26. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30 (2): 121-32
27. Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000; 25 (1): 49-58
28. Fabre E, Chevret S, Piechaud JF, et al. An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method. Br J Clin Pharmacol 1998; 46: 395-401
29. Guidance for industry: population pharmacokinetics, February 1999 [online]. Bethesda (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Available from URL: http://www.fda.gov/cder/guidance/1852fnl.pdf [Accessed 2004 Dec 1]
30. Exposure-response relationships: study design, data analysis, and regulatory applications. 1998; 46: 395-401. Bethesda (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) April 2003 [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/99/backgrd/3457b2a.pdf [Accessed 2004 Dec 1]